Project Grant R21NS135376

Award Date 5/15/24
Completion Date 4/30/26
Dollars Obligated $610K
Funding Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
This Project Grant award of $1,693,159, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into the role of N-terminal acetylation (ACN) in regulating alpha-synuclein (AS) stability, function, and therapeutic targeting for synucleinopathies such as Parkinson's disease (PD) and Alzheimer's disease-related dementias (ADRD). The research aims...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $155,000.00 to The Johns Hopkins University to develop a mouse model for studying the impact of the AIMP2 R65C variant on Parkinson's disease pathogenesis. The key objectives are to: 1) Create an AIMP2 R65C knock-in mouse model and characterize its motor phenotype and brain...
This Project Grant award of $616,200.00, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders, will support research to explore the role of neuromelanin accumulation in dopamine neurons and its impact on Parkinson's disease. The primary awardee, the Oklahoma Medical Research Foundation (OMRF), will leverage expertise across three established labs to investigate the...
This Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to understand the role of 14-3-3θ phosphorylation in regulating alpha-synuclein aggregation and transport, which are key factors in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The $2,723,954 award to the University of Alabama at Birmingham will fund a...
This three-year, $8.29 million project grant from the National Institutes of Health National Institute on Aging will support the development of full human gene replacement mouse models of Alzheimer's disease. Funded under the Aging Research program (CFDA 93.866), the Regents of the University of Minnesota will generate mouse lines with replacement of key Alzheimer's-related genes, including APP, PSEN1, PSEN2, MAPT, APOE, TREM2, MS4A, and INPP5D, with their full human orthologues. Control lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to examine the role of the LRP10 gene in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. The $457,875 award, granted on May 1, 2025, will fund the generation and characterization of an LRP10 knockout mouse model to investigate the physiological functions and pathological roles of LRP10 in these neurodegenerative disorders. The research, conducted by the...
The Research Foundation for the State University of New York (RF SUNY) received a $158,379 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The funding will support research to understand how the protein alpha-synuclein (α-syn) contributes to mitochondrial dysfunction in Parkinson's disease (PD). The project aims to isolate the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $682,493 to the Albert Einstein College of Medicine to elucidate the role of aberrant histone acetylation in the pathogenesis of Parkinson's disease and related synucleinopathies. The research involves utilizing a human pluripotent stem cell-based discovery platform...

DNAJC13 P.N860S AS A PHYSIOLOGIC MODEL OFALPHA-SYNUCLEIN OVEREXPRESSION - PROJECT SUMMARY/ABSTRACT PARKINSON'S DISEASE (PD) IS A DEBILITATING NEURODEGENERATIVE DISORDER ASSOCIATED WITH THE LOSS OF DOPAMINE PRODUCING NEURONS AND THE ACCUMULATION OF PROTEIN AGGREGATES RICH IN A-SYNUCLEIN (LEWY BODIES). WHILE THE CAUSES OF PD ARE NOT FULLY KNOWN, RARE FAMILIES WITH MONOGENIC FORMS PROVIDE TRANSLATABLE TARGETS AND THE MODELS IN WHICH TO TEST NOVEL THERAPEUTIC STRATEGIES. FOR EXAMPLE, A-SYNUCLEIN (SNCA) WAS DISCOVERED TO BE THE MAJOR PROTEIN CONSTITUENT OF LEWY BODIES ONLY AFTER THE GENE ENCODING IT WAS LINKED TO FAMILIAL PD. OUR DISCOVERY OF SNCA MULTIPLICATIONS SUBSEQUENTLY PROVIDED THE RATIONALE AND MODELS TO DEVELOP MULTIPLE APPROACHES TO LOWER ASYN EXPRESSION THAT ARE CURRENTLY IN CLINICAL TRIALS. IN 2014, WE GENETICALLY LINKED A MISSENSE MUTATION (P.N855S) IN DNAJC13 (ENCODING RECEPTOR-MEDIATED ENDOCYTOSIS-8; RME-8) TO LATE-ONSET AUTOSOMAL-DOMINANT PARKINSONISM IN MULTI-INCIDENT MENNONITE KINDREDS (RME-8 PD). AFFECTED FAMILY MEMBERS HAD POST-MORTEM LEWY PATHOLOGY RICH IN A-SYNUCLEIN (ASYN) AND NEURONAL LOSS IN THE SUBSTANTIA NIGRA (SNPC). RME-8 IS A DNAJ-DOMAIN- CONTAINING PROTEIN THAT, TOGETHER WITH HEAT SHOCK COGNATE 70 (HSC70), STIMULATES: 1) THE REFOLDING OF MISFOLDED PROTEINS AND; 2) CLATHRIN REMOVAL FROM VESICLES. HENCE, LOSS OF RME-8 LEADS TO AN ACCUMULATION OF CLATHRIN COATED VESICLES, HYPER EXTENDED MEMBRANE TUBULES AND THE AGGREGATION OF CARGOS. GIVEN THIS BACKGROUND, WE DEVELOPED A DNAJC13 P. N860S KNOCK-IN (DKIHET; CORRESPONDING TO HUMAN P. N855S MUTATION) MOUSE MODEL. PRELIMINARY STUDIES IN DKIHET BRAIN AT 3 MONTHS OF AGE REVEAL THE RME-8 MUTATION: 1) INCREASES SOLUBLE MONOMERIC ASYN AND CLATHRIN COATED INTERMEDIATES; 2) CAUSES SYNAPTIC DELAY FOLLOWING REPETITIVE STIMULATION, AND; 3) IMPAIRS MOVEMENT INITIATION (RESULTING IN FREEZING) IN OPEN FIELD BEHAVIOR. THE PHENOTYPES DKIHET CONFERS ARE CONSISTENT WITH A PATHOLOGIC GAIN OF FUNCTION AND REMINISCENT OF A 'SYNAPTOPATHY. IN THIS PROPOSAL WE AIM TO MORE FULLY CHARACTERIZE THE DKIHET MODEL WITH RESPECT TO MUTANT AND WILDTYPE RME-8 PROTEIN-BINDING IN SYNAPTOSOMES FROM MICRODISSECTED STRIATUM. WE WILL MORE FULLY CHARACTERIZE DIFFERENCES IN ASYN BIOLOGY, INCLUDING PHOSPHORYLATED AND HIGHER MOLECULAR WEIGHT SPECIES. WE WILL ALSO LOOK AT THE MUTATION'S IMPACT ON DOPAMINERGIC FUNCTION, INCLUDING BIOCHEMICAL, PHYSIOLOGIC AND MORPHOLOGIC ASSESSMENTS. LASTLY, GIVEN RME-8 IS ALSO AN INTERFERON- RESPONSIVE GENE WE WILL EXPLORE NEUROIMMUNE BIOLOGY AND FOCUS ON MICROGLIAL PRUNING OF DOPAMINERGIC TERMINALS. COMPLETION OF THESE EXPERIMENTS WILL DEFINE THE BIOLOGIC ROLE OF DNAJC13 P.N855S, HIGHLIGHT ITS MECHANISM OF ACTION IN DISEASE PATHOGENESIS, AND DEMONSTRATE THE UTILITY OF DKIHET MICE.

Posted 5/14/24